Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in the United States

Steven J. Frank, Peter D. Grimm, John E. Sylvester, Gregory S. Merrick, Brian J. Davis, Anthony Zietman, Brian J. Moran, David C. Beyer, Mack Roach, Daniel H. Clarke, Richard G. Stock, W. Robert Lee, Jeff M. Michalski, Kent E. Wallner, Mark Hurwitz, Louis Potters, Deborah A. Kuban, Bradley R. Prestidge, Robyn Vera, Shannon HathawayJohn C. Blasko

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Purpose: This study is aimed at understanding and defining the current patterns of care with respect to prostate brachytherapy for patients with intermediate-risk localized disease in the combined academic and community setting. Methods and materials: A nomogram-based survey was developed at the Seattle Prostate Institute defining the accepted criteria for intermediate-risk prostate cancer. Patients were defined as having intermediate-risk prostate cancer if they met one of the following criteria: prostate-specific antigen (PSA) >10 ng/dL, Gleason score (GS) ≥7, or cT2b or cT2c disease. Additional potential predictive factors including perineural invasion (PNI), GS 3 + 4 vs. 4 + 3, and high-volume disease were included. Results: In the absence of PNI, all of those surveyed would perform monotherapy for intermediate-risk patients, GS 7 (3 + 4) or PSA 10-20, with cT1c and <30% cores +. Up to 80% would perform monotherapy for patients with cT1c, GS 7 (4 + 3), and <30% cores +. Eighty to 90% of physicians would perform an implant alone with cT2a and either a PSA of 10-20 or GS of 7 (3 + 4) and <30% cores +. Fifty to 60% of those surveyed stated that they would treat a patient with cT2b disease, GS 7 (3 + 4), or PSA 11-20, with less than two-thirds of the biopsy cores positive in the absence of PNI. Conclusions: This Patterns of Care (POC) study reveals that certain subsets of intermediate-risk localized prostate cancer patients are considered appropriate candidates for an interstitial implant alone.

Original languageEnglish (US)
Pages (from-to)2-8
Number of pages7
JournalBrachytherapy
Volume6
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Neoplasm Grading
Prostatic Neoplasms
Radiotherapy
Prostate-Specific Antigen
Prostate
Nomograms
Brachytherapy
Surveys and Questionnaires
Physicians
Biopsy

Keywords

  • Brachytherapy
  • Intermediate risk
  • Prostate

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer : A survey of practice patterns in the United States. / Frank, Steven J.; Grimm, Peter D.; Sylvester, John E.; Merrick, Gregory S.; Davis, Brian J.; Zietman, Anthony; Moran, Brian J.; Beyer, David C.; Roach, Mack; Clarke, Daniel H.; Stock, Richard G.; Robert Lee, W.; Michalski, Jeff M.; Wallner, Kent E.; Hurwitz, Mark; Potters, Louis; Kuban, Deborah A.; Prestidge, Bradley R.; Vera, Robyn; Hathaway, Shannon; Blasko, John C.

In: Brachytherapy, Vol. 6, No. 1, 01.2007, p. 2-8.

Research output: Contribution to journalArticle

Frank, SJ, Grimm, PD, Sylvester, JE, Merrick, GS, Davis, BJ, Zietman, A, Moran, BJ, Beyer, DC, Roach, M, Clarke, DH, Stock, RG, Robert Lee, W, Michalski, JM, Wallner, KE, Hurwitz, M, Potters, L, Kuban, DA, Prestidge, BR, Vera, R, Hathaway, S & Blasko, JC 2007, 'Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in the United States', Brachytherapy, vol. 6, no. 1, pp. 2-8. https://doi.org/10.1016/j.brachy.2006.09.004
Frank, Steven J. ; Grimm, Peter D. ; Sylvester, John E. ; Merrick, Gregory S. ; Davis, Brian J. ; Zietman, Anthony ; Moran, Brian J. ; Beyer, David C. ; Roach, Mack ; Clarke, Daniel H. ; Stock, Richard G. ; Robert Lee, W. ; Michalski, Jeff M. ; Wallner, Kent E. ; Hurwitz, Mark ; Potters, Louis ; Kuban, Deborah A. ; Prestidge, Bradley R. ; Vera, Robyn ; Hathaway, Shannon ; Blasko, John C. / Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer : A survey of practice patterns in the United States. In: Brachytherapy. 2007 ; Vol. 6, No. 1. pp. 2-8.
@article{dbbd36a4e9b44de1905e7eeaa1905292,
title = "Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in the United States",
abstract = "Purpose: This study is aimed at understanding and defining the current patterns of care with respect to prostate brachytherapy for patients with intermediate-risk localized disease in the combined academic and community setting. Methods and materials: A nomogram-based survey was developed at the Seattle Prostate Institute defining the accepted criteria for intermediate-risk prostate cancer. Patients were defined as having intermediate-risk prostate cancer if they met one of the following criteria: prostate-specific antigen (PSA) >10 ng/dL, Gleason score (GS) ≥7, or cT2b or cT2c disease. Additional potential predictive factors including perineural invasion (PNI), GS 3 + 4 vs. 4 + 3, and high-volume disease were included. Results: In the absence of PNI, all of those surveyed would perform monotherapy for intermediate-risk patients, GS 7 (3 + 4) or PSA 10-20, with cT1c and <30{\%} cores +. Up to 80{\%} would perform monotherapy for patients with cT1c, GS 7 (4 + 3), and <30{\%} cores +. Eighty to 90{\%} of physicians would perform an implant alone with cT2a and either a PSA of 10-20 or GS of 7 (3 + 4) and <30{\%} cores +. Fifty to 60{\%} of those surveyed stated that they would treat a patient with cT2b disease, GS 7 (3 + 4), or PSA 11-20, with less than two-thirds of the biopsy cores positive in the absence of PNI. Conclusions: This Patterns of Care (POC) study reveals that certain subsets of intermediate-risk localized prostate cancer patients are considered appropriate candidates for an interstitial implant alone.",
keywords = "Brachytherapy, Intermediate risk, Prostate",
author = "Frank, {Steven J.} and Grimm, {Peter D.} and Sylvester, {John E.} and Merrick, {Gregory S.} and Davis, {Brian J.} and Anthony Zietman and Moran, {Brian J.} and Beyer, {David C.} and Mack Roach and Clarke, {Daniel H.} and Stock, {Richard G.} and {Robert Lee}, W. and Michalski, {Jeff M.} and Wallner, {Kent E.} and Mark Hurwitz and Louis Potters and Kuban, {Deborah A.} and Prestidge, {Bradley R.} and Robyn Vera and Shannon Hathaway and Blasko, {John C.}",
year = "2007",
month = "1",
doi = "10.1016/j.brachy.2006.09.004",
language = "English (US)",
volume = "6",
pages = "2--8",
journal = "Brachytherapy",
issn = "1538-4721",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer

T2 - A survey of practice patterns in the United States

AU - Frank, Steven J.

AU - Grimm, Peter D.

AU - Sylvester, John E.

AU - Merrick, Gregory S.

AU - Davis, Brian J.

AU - Zietman, Anthony

AU - Moran, Brian J.

AU - Beyer, David C.

AU - Roach, Mack

AU - Clarke, Daniel H.

AU - Stock, Richard G.

AU - Robert Lee, W.

AU - Michalski, Jeff M.

AU - Wallner, Kent E.

AU - Hurwitz, Mark

AU - Potters, Louis

AU - Kuban, Deborah A.

AU - Prestidge, Bradley R.

AU - Vera, Robyn

AU - Hathaway, Shannon

AU - Blasko, John C.

PY - 2007/1

Y1 - 2007/1

N2 - Purpose: This study is aimed at understanding and defining the current patterns of care with respect to prostate brachytherapy for patients with intermediate-risk localized disease in the combined academic and community setting. Methods and materials: A nomogram-based survey was developed at the Seattle Prostate Institute defining the accepted criteria for intermediate-risk prostate cancer. Patients were defined as having intermediate-risk prostate cancer if they met one of the following criteria: prostate-specific antigen (PSA) >10 ng/dL, Gleason score (GS) ≥7, or cT2b or cT2c disease. Additional potential predictive factors including perineural invasion (PNI), GS 3 + 4 vs. 4 + 3, and high-volume disease were included. Results: In the absence of PNI, all of those surveyed would perform monotherapy for intermediate-risk patients, GS 7 (3 + 4) or PSA 10-20, with cT1c and <30% cores +. Up to 80% would perform monotherapy for patients with cT1c, GS 7 (4 + 3), and <30% cores +. Eighty to 90% of physicians would perform an implant alone with cT2a and either a PSA of 10-20 or GS of 7 (3 + 4) and <30% cores +. Fifty to 60% of those surveyed stated that they would treat a patient with cT2b disease, GS 7 (3 + 4), or PSA 11-20, with less than two-thirds of the biopsy cores positive in the absence of PNI. Conclusions: This Patterns of Care (POC) study reveals that certain subsets of intermediate-risk localized prostate cancer patients are considered appropriate candidates for an interstitial implant alone.

AB - Purpose: This study is aimed at understanding and defining the current patterns of care with respect to prostate brachytherapy for patients with intermediate-risk localized disease in the combined academic and community setting. Methods and materials: A nomogram-based survey was developed at the Seattle Prostate Institute defining the accepted criteria for intermediate-risk prostate cancer. Patients were defined as having intermediate-risk prostate cancer if they met one of the following criteria: prostate-specific antigen (PSA) >10 ng/dL, Gleason score (GS) ≥7, or cT2b or cT2c disease. Additional potential predictive factors including perineural invasion (PNI), GS 3 + 4 vs. 4 + 3, and high-volume disease were included. Results: In the absence of PNI, all of those surveyed would perform monotherapy for intermediate-risk patients, GS 7 (3 + 4) or PSA 10-20, with cT1c and <30% cores +. Up to 80% would perform monotherapy for patients with cT1c, GS 7 (4 + 3), and <30% cores +. Eighty to 90% of physicians would perform an implant alone with cT2a and either a PSA of 10-20 or GS of 7 (3 + 4) and <30% cores +. Fifty to 60% of those surveyed stated that they would treat a patient with cT2b disease, GS 7 (3 + 4), or PSA 11-20, with less than two-thirds of the biopsy cores positive in the absence of PNI. Conclusions: This Patterns of Care (POC) study reveals that certain subsets of intermediate-risk localized prostate cancer patients are considered appropriate candidates for an interstitial implant alone.

KW - Brachytherapy

KW - Intermediate risk

KW - Prostate

UR - http://www.scopus.com/inward/record.url?scp=33846599235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846599235&partnerID=8YFLogxK

U2 - 10.1016/j.brachy.2006.09.004

DO - 10.1016/j.brachy.2006.09.004

M3 - Article

C2 - 17284379

AN - SCOPUS:33846599235

VL - 6

SP - 2

EP - 8

JO - Brachytherapy

JF - Brachytherapy

SN - 1538-4721

IS - 1

ER -